drugset / Trial / NCT07083960
OM336 in Autoimmune Cytopenias
NaSequentialOpen-labelTreatment
Summary
An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of subcutaneously dosed OM336 in adult participants with autoimmune cytopenias.
Timeline
- Start
- 2025-08-01
- Primary completion
- 2026-12
- Completion
- 2027-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OM336 | Unknown | — | Subcutaneous |